Rezdiffra Improved Liver Health in Genetic Subgroups
A study found that patients with MASH-associated genetic variants responded positively to Madrigal Pharmaceuticals' treatment.
Updated on Oct. 14, 2026 in Diseases — General
Live Poll
Would you want genetic testing results to guide your choice of prescription medications?
Madrigal Pharmaceuticals reported that Rezdiffra effectively improved liver damage in patients carrying specific genetic risk variants for metabolic dysfunction-associated steatohepatitis (MASH). These results were confirmed through a secondary analysis of the Phase 3 MAESTRO-NASH trial.
Why it matters
The analysis sought to determine if common genetic differences that influence disease progression affect how patients respond to Rezdiffra treatment. Confirming efficacy across these genetic risk factors helps broaden the understanding of how precision medicine can be applied to MASH.
Researchers analyzed patient data regarding 5 specific genes associated with MASH progression. The study confirmed that Rezdiffra treatment led to improvements in liver fibrosis and MASH resolution among these genetic risk carriers.
The players
Madrigal Pharmaceuticals
This biopharmaceutical company based in Conshohocken, Pennsylvania, focuses on developing therapies for non-alcoholic steatohepatitis.
Journal of Hepatology
This peer-reviewed medical publication serves as an official journal for the European Association for the Study of the Liver.
The details
The analysis, published in the Journal of Hepatology, demonstrated that patients with variants in the PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7 genes showed consistent improvements in liver health. The treatment also resulted in significant reductions in liver fat as measured by MRI-PDFF.
Timeline
October 14, 2026: Findings were published in the Journal of Hepatology.
The Big Picture
This analysis builds upon the framework established by the Phase 3 MAESTRO-NASH trial to evaluate how genetic signatures influence therapeutic outcomes. It represents a shift toward understanding personalized responses in complex metabolic liver diseases.
This research provides clinical evidence that Rezdiffra remains an effective option even for patients with high-risk genetic predispositions to MASH. It supports healthcare providers in making informed treatment decisions based on a patient's specific genetic profile.
The takeaway
The study suggests that genetic testing could play a larger role in personalizing treatment plans for those suffering from MASH. Patients are encouraged to discuss their genetic health markers and available treatment options with their primary care providers or hepatologists.
What happens next
Researchers intend to conduct similar secondary analyses to evaluate the efficacy of other approved and investigational therapies for MASH patients.
Further reading
Learn more about the latest research in Diseases — General.
Source note: This article includes information reported by MyChesCo.
Live Poll
Would you want genetic testing results to guide your choice of prescription medications?
